A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Trial Profile

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Cetirizine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Pharmacokinetics
  • Sponsors Aciex Therapeutics
  • Most Recent Events

    • 14 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 27 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top